Demant A/S (LON:0RGT)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 7.12B +20.1% |
| Revenue (ttm) | 2.84B +9.1% |
| Net Income | 185.89M -30.0% |
| EPS | 0.88 -29.3% |
| Shares Out | n/a |
| PE Ratio | 38.29 |
| Forward PE | 19.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,264 |
| Open | 296.20 |
| Previous Close | 295.30 |
| Day's Range | 291.80 - 297.20 |
| 52-Week Range | 175.00 - 299.20 |
| Beta | 0.76 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Demant
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark. [Read more]
Financial Performance
In 2025, Demant's revenue was 22.97 billion, an increase of 2.46% compared to the previous year's 22.42 billion. Earnings were 1.55 billion, a decrease of -35.27%.
Financial numbers in DKK Financial StatementsNews
Demant price target raised to DKK 296 from DKK 290 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Demant (WILYY) to DKK 296 from DKK 290 and keeps an Overweight rating on the shares.
Demant price target raised to DKK 315 from DKK 250 at JPMorgan
JPMorgan analyst David Adlington raised the firm’s price target on Demant (WILYY) to DKK 315 from DKK 250 and keeps an Overweight rating on the shares.
Demant Earnings Call Transcript: Q2 2026
Strong H1 2026 performance with 15% revenue growth, margin expansion, and robust cash flow, driven by hearing aids and KIND acquisition. Upgraded outlook projects 6%-7% organic growth and EBIT of DKK 4.4-4.8 billion, with continued innovation from Oticon Reveal.
Demant Quarterly report: Q2 2026
Demant has published its Q2 2026 quarterly earnings report on August 12, 2026.
Demant Slides: Q2 2026
Demant has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
Demant downgraded to Hold from Buy at Danske Bank
Danske Bank analyst Carsten Madsen downgraded Demant (WILYY) to Hold from Buy with a DKK 280 price target
Demant price target raised to DKK 325 from DKK 235 at Citi
Citi raised the firm’s price target on Demant (WILYY) to DKK 325 from DKK 235 and keeps a Buy rating on the shares.
Demant downgraded to Neutral from Buy at UBS
UBS downgraded Demant (WILYY) to Neutral from Buy with a price target of DKK 284, up from DKK 273. The firm cites valuation and a lack of upside potential to…
Demant downgraded to Market Perform from Outperform at Bernstein
Bernstein downgraded Demant (WILYY) to Market Perform from Outperform with a DKK 276 price target The firm cites valuation for the downgrade, saying the shares are already pricing in a…
Demant price target raised to DKK 258 from DKK 226 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs raised the firm’s price target on Demant (WILYY) to DKK 258 from DKK 226 and keeps a Hold rating on the shares. Published first on…
Demant upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Aisyah Noor upgraded Demant (WILYY) to Overweight from Equal Weight with a price target of DKK 290, up from DKK 210. The firm says signs of a…
Demant upgraded to Buy from Underperform at BofA
BofA upgraded Demant (WILYY) to Buy from Underperform with a price target of DKK 280, up from DKK 170. The firm sees upside to the company’s guidance given a recovery…
Demant price target raised to DKK 226 from DKK 211 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Demant (WILYY) to DKK 226 from DKK 211 and keeps a Hold rating on the shares.
Demant Earnings Call Transcript: Q1 2026
Strong Q1 2026 performance with 6% organic and 10% acquisitive growth, led by Oticon Zeal’s successful launch and KIND integration. Guidance maintained, with lower end now less likely due to robust momentum and positive market trends.
Demant Earnings release: Q1 2026
Demant released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Demant Slides: Q1 2026
Demant has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Demant price target raised to DKK 210 from DKK 207 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Demant (WILYY) to DKK 210 from DKK 207 and keeps an Equal Weight rating on the shares.
Demant upgraded to Buy from Hold at Jefferies
Jefferies upgraded Demant (WILYY) to Buy from Hold with a price target of DKK 245, down from DKK 255. The firm sees share upside in 2026 from the company’s easy…
Demant upgraded to Buy from Hold at Nordea
Nordea analyst Martin Brenoe upgraded Demant (WILYY) to Buy from Hold with a DKK 230 price target
Demant price target lowered to DKK 235 from DKK 290 at Citi
Citi lowered the firm’s price target on Demant (WILYY) to DKK 235 from DKK 290 and keeps a Buy rating on the shares.
Demant price target lowered to DKK 211 from DKK 242 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Demant (WILYY) to DKK 211 from DKK 242 and keeps a Hold rating on the shares. Published first on…
Demant downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas downgraded Demant (WILYY) to Neutral from Outperform with a DKK 200 price target
Demant price target lowered to DKK 207 from DKK 221 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Demant (WILYY) to DKK 207 from DKK 221 and keeps an Equal Weight rating on the shares. Published first…
Demant price target lowered to DKK 250 from DKK 288 at JPMorgan
JPMorgan lowered the firm’s price target on Demant (WILYY) to DKK 250 from DKK 288 and keeps an Overweight rating on the shares.
Demant Earnings Call Transcript: Q4 2025
Reported 2% organic growth for 2025, with strong Q4 performance in Hearing Care and Diagnostics, but margin pressure from ASP and mix. 2026 guidance targets 3%-6% organic growth, DKK 4.1-4.5bn EBIT, and cost savings, with Zeal rollout and KIND acquisition as key drivers.